Opinion
Published on 29 Jul 2020
Rationale for Considering Oral Idasanutlin as a Therapeutic Option for COVID-19 Patients
in Translational Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2020.01156
- 4,057 views
- 18 citations

